$0.04 EPS Expected for Champions Oncology Inc (CSBR) This Quarter

Share on StockTwits

Equities analysts forecast that Champions Oncology Inc (NASDAQ:CSBR) will announce earnings per share of $0.04 for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Champions Oncology’s earnings. The highest EPS estimate is $0.05 and the lowest is $0.03. The business is expected to announce its next quarterly earnings report on Thursday, December 6th.

On average, analysts expect that Champions Oncology will report full year earnings of $0.17 per share for the current fiscal year, with EPS estimates ranging from $0.15 to $0.19. For the next fiscal year, analysts forecast that the firm will post earnings of $0.25 per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Champions Oncology.

Champions Oncology (NASDAQ:CSBR) last announced its quarterly earnings data on Thursday, September 13th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.03. The business had revenue of $6.23 million during the quarter, compared to analysts’ expectations of $5.85 million. Champions Oncology had a negative return on equity of 97.02% and a negative net margin of 1.63%.

A number of research analysts have issued reports on CSBR shares. Zacks Investment Research upgraded Champions Oncology from a “hold” rating to a “strong-buy” rating and set a $12.00 price objective for the company in a research note on Monday, September 17th. Craig Hallum started coverage on Champions Oncology in a research note on Tuesday, July 17th. They set a “buy” rating and a $12.00 price objective for the company. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $11.33.

In other Champions Oncology news, Director Joel Ackerman sold 22,535 shares of Champions Oncology stock in a transaction on Monday, October 1st. The stock was sold at an average price of $17.02, for a total value of $383,545.70. Following the completion of the sale, the director now owns 1,021,731 shares of the company’s stock, valued at approximately $17,389,861.62. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel Newman Mendelson sold 8,333 shares of Champions Oncology stock in a transaction on Thursday, September 20th. The stock was sold at an average price of $13.02, for a total value of $108,495.66. Following the completion of the sale, the director now directly owns 62,500 shares of the company’s stock, valued at approximately $813,750. The disclosure for this sale can be found here. 44.30% of the stock is currently owned by company insiders.

Institutional investors have recently bought and sold shares of the business. Perkins Capital Management Inc. bought a new stake in shares of Champions Oncology in the 2nd quarter worth $653,000. Tocqueville Asset Management L.P. bought a new stake in shares of Champions Oncology in the second quarter worth $729,000. Renaissance Technologies LLC grew its holdings in shares of Champions Oncology by 63.3% in the second quarter. Renaissance Technologies LLC now owns 100,600 shares of the biotechnology company’s stock worth $638,000 after acquiring an additional 39,000 shares during the period. Ingalls & Snyder LLC bought a new stake in shares of Champions Oncology in the third quarter worth $2,772,000. Finally, Essex Investment Management Co. LLC bought a new stake in shares of Champions Oncology in the second quarter worth $646,000. 40.68% of the stock is owned by institutional investors and hedge funds.

NASDAQ:CSBR traded up $0.66 during trading hours on Friday, reaching $14.75. 3,133 shares of the company traded hands, compared to its average volume of 187,339. The stock has a market capitalization of $148.26 million, a price-to-earnings ratio of -106.57 and a beta of 0.57. Champions Oncology has a 1 year low of $3.05 and a 1 year high of $17.90. The company has a current ratio of 0.73, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23.

About Champions Oncology

Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.

Featured Article: Investing in Growth Stocks

Get a free copy of the Zacks research report on Champions Oncology (CSBR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Champions Oncology (NASDAQ:CSBR)

Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply